stock move rapidli w/ momentum post-sitra nivo data report
move like driven allur final crack part kra code
also b/c posit commentari regard relat recent
move open-label clin test though enthus base small
molecul approach unmet need believ still early-stag base
progress clinic sitra data kra market oppti adj
increas pt vs prior
develop small molecul inhibitorsthat interact coval
w/ program month ahead given
similar initi data havereadthrough
initi clinic data expect either titl
impli potenti clin data abstract post plan
report clinic data anticip earli cut potenti placehold
text abstract w/ meaning updat confer
also possibl clin data report titl
data aacr/asco would expect pt initi focu
orr given start rel higher dose level ph believ
investor expect least pr rate base moa probabl estimate de-
risk believ translat
disclos preclin data precursor kra molecul
aacr ra confer assum precursor molecul function in-lin
w/ clin candid clin candid
form coval bond w/ lock
inact gdp-bound form conflict w/ tumor cell prefer activ gtp
form aacr ra report precursor show pm
cell low plasma protein bind impli larger fraction unbound drug may
improv target engag -- characterist could translat favor tx
window increas chanc clin activ xenograft
model show rapid tumor growth inhibit dose w/ high-dos produc
day post cessat dose anim tumor free highest
dose tumor free mid-dos
also believ clinic candid favor preclin/in vitro properti
demonstr cellular potenc nm w/ select mutant
vs wt kra compound shown broad-spectrum anti-tumor activ
preclin model includ respons w/ exist co-mut
predict human oral bioavail half-lif hour
believ favor par w/ target oncolog small molecul
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
though public interest suggest resist unlik present
time tx believ much still learn highlight durabl risk us
public yale lab w/ author includ highlight relev
activ mutat nice evalu kra lung tumor
sampl two assess eight passag pdx model provid
assess time/tumor evolut analys result describ
pleas see import disclosur inform page report
current orr ci-refractori sitra opdivo combo erod
pt treat
kra dose first patient w/ earli in-lin w/
data
larg sitra ci vs docetaxel ph iii start time enrol
plan
genetically-select patient enrol sitra studi
increas diagnost use expand
progress w/ partner bgne ex-u develop
kra enrol quickli clinic data durabl better-
ph iii sitra ci trial enrol faster expect posit
orr
partner program w/ bgne materi quicker
price target use blend dcf ep multipl
sitravatinib combo/mono efficaci consist and/or
unexpect safeti issu lead program discontinu
price target use blend dcf ep multipl
valid emerg cancer approach competit
advanc need execut larg ph iii
sitravatinib nivo patient fail prior checkpoint
inhibitor show promis activ even though ph iii
larg docetaxel compar set best-cas chanc
kra data could transform stock
 initi ph iii sitra nivo ci-refractori nsclc
 phase updat sitra mono nsclc
 ph ii initi poc data sitra nivo ci refractori
 interim analysi sitra ci nsclc
 final analysi sitra ci nsclc
pleas see import disclosur inform page report
financi summari market data
estim valuat
pleas see import disclosur inform page report
probabl best get sens resist w/ kra howev highlight
consider experi directli assess resist time tx
predict mutat could confer fit benefit subclon -- know
resist pathway could aris treatment inhibit kra via coval
bind know resist pathway could aris base use
oncolog treatment use may induc unpredict
alter given tissu heterogen everi tumor cell posit
know resist pathway could aris base vivo human tumor
microenvironment/immun system pressur may provid advantag
tumor cell therefor though target translat respons would get
approv use creat meaning market oppti believ rang outcom
valuat possibl conting durabl well competit dynam w/
provid surpris safeti orr disappoint
anticip primari market opportun risk could
treatment durations/dur
egfr good exampl resist pathway/gatekeep mutat
develop due early-gen tki may limit market potenti albeit also creat new
oppti next-gen tagrisso primarili reduc durat treatment
model adjust lead pt increas
increas sitra po increas kra po increas
kra penetr rate decreas average durat tx mo vs mo prior pt
pleas see import disclosur inform page report
pleas see import disclosur inform page report
mirati san diego ca-bas clinic development-stag compani focus oncolog product target
precis defin patient popul mrtx lead drug standout receptor tyrosin kinas inhibitor met/axl target
pt blend dcf prob-adj ep analys risk efficaci toxic competit
pt base probability-bas dcf risk includ ip litig biosimilar price competit
pt base pipeline-adjust dcf ep estim risk competit pipelin disappoint
mauri raycroft ph certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
mitchel kapoor certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
jefferi llc act financi advisor kite pharma kite sale compani
jefferi group llc make market secur adr
jefferi group llc make market secur adr inc
jefferi group llc make market secur adr inc
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate
secur averag secur price consist expect total return price appreci plu yield plu minu
pleas see import disclosur inform page report
within period under-perform rate secur averag secur price consist expect
total return price appreci plu yield minu less within period
nr invest rate price target temporarili suspend suspens complianc applic
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic
secur regul prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project
opinion invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ
restrict analys market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash
price-to-earnings sum part net asset valu dividend return return equiti roe next month
jefferi franchis pick includ stock select among best stock idea equiti analyst month period
stock select base fundament analysi may take account factor analyst convict differenti
analysi favor risk/reward ratio invest theme jefferi analyst recommend jefferi franchis pick
includ buy rate stock number vari depend analyst recommend inclus stock ad
new opportun aris remov reason inclus chang stock met desir return longer rate
buy and/or trigger stop loss stock day volatil bottom quartil stock continu
stop loss remaind stop franchis pick intend repres recommend portfolio stock
sector base may note believ pick fall within invest style growth valu
risk may imped achiev price target
report prepar gener circul provid invest recommend specif individu investor
financi instrument discuss report may suitabl investor investor must make
invest decis base upon specif invest object financi situat util financi advisor
deem necessari past perform financi instrument recommend report taken indic
guarante futur result price valu incom financi instrument mention report rise well
fall may affect chang econom financi polit factor financi instrument denomin currenc
investor home currenc chang exchang rate may advers affect price valu incom deriv
financi instrument describ report addit investor secur adr whose valu affect
currenc underli secur effect assum currenc risk
compani mention report
pleas see import disclosur inform page report
